Cell News and Research

RSS

Unraveling the mystery behind lower cancer risks in type 1 diabetes patients

New research in The Journal of Immunology uncovers how high blood sugar (hyperglycemia) and type 1 diabetes (T1D) may protect against certain cancers like melanoma, breast and colon cancer. T1D has been associated with a decreased risk of certain cancers, but the exact reasons why have remained a mystery. New data from studies in mice, now shows that it could be due to changes in immune cells, called T cells, caused by hyperglycemia.

29 Oct 2026

ATCC selected by ARPA-H to support next-generation BioStabilization technologies

ATCC has been selected by the Advanced Research Projects Agency for Health (ARPA-H) as an affiliate to provide independent verification and validation (IV&V) for its BioStabilization Systems (BoSS) program.

From ATCC 29 Oct 2026

Mutated neutrophils may trigger immune attacks in lupus

Scientists at La Jolla Institute for Immunology (LJI) and the University of Washington (UW) have discovered that patients with lupus have unusual mutations that may turn their bodies into battlegrounds.

28 Oct 2026

Thyroid cancer risks and medication timing with oral GLP-1s

Like most prescriptions, glucagon-like peptide 1 (GLP-1) medications to manage weight come with potential risks.

28 Oct 2026

COMPASS pathway helps regulatory T cells prevent intestinal inflammation

Trillions of bacteria live in the human gut without triggering an immune response. Scientists at St. Jude Children's Research Hospital have now discovered a gene-regulatory pathway that helps maintain this delicate balance.

28 Oct 2026

Ketones may change sleep patterns, but not always for the better

Researchers reviewed animal and human studies and found that ketone bodies may affect sleep stages through energy metabolism and cellular signaling, with the clearest direct evidence involving acetoacetate in mice. They reported mixed human findings and called for controlled studies to separate ketone-specific effects from changes linked to diet, disease, circadian timing, and physiological stress.

28 Oct 2026

UCSF scientists develop smart CAR-T cells to fight childhood brain tumors

Scientists at UC San Francisco have engineered CAR-T cells that stay dormant until they reach the brain, where they switch on and destroy tumor cells.

28 Oct 2026

Inflammatory macrophages identified as drivers of chronic joint osteoarthritis

Researchers have identified a group of inflammatory macrophages that drive osteoarthritis by sustaining inflammation in the synovium – a layer of connective tissue within joints – and show that they can target these immune cells to treat the disease in mice.

28 Oct 2026

Dual-targeting antibody successfully tackles multiple tumor types in mice

A novel antibody therapy empowers the immune system's tumor-fighting capabilities in mice by targeting immune-suppressing T cells with greater precision than previous approaches, according to new work.

28 Oct 2026

University of Utah researchers discover backup energy system in the heart

The heart is the hardest-working muscle in the body, beating constantly no matter what the body's energy reserves look like.

28 Oct 2026

Targeted drug combination extends survival in advanced kidney cancer

Results of a phase 1/2 trial led by Roswell Park Comprehensive Cancer Center show that combining the targeted therapies bevacizumab (Avastin) and pazopanib (Votrient) significantly extends both progression-free and overall survival in patients with the most common type of kidney cancer.

28 Oct 2026

Landmark studies map how genetic differences drive human diseases

In three landmark studies published in Nature today, Australian researchers have made major advances in our understanding of how genetic differences between people influence disease.

28 Oct 2026

Study identifies common mechanism behind widespread cancer mutations

A family of mutations seen in about 20% of human cancers drives malignancy by changing the accessibility of genes to a particular regulatory protein, according to a study by Weill Cornell Medicine investigators.

28 Oct 2026

Japan's new law advances reproductive genome editing governance

A Hiroshima University researcher outlines advantages of Japan's new law that prohibits the transfer of genome-edited human embryos or germ cells into the human reproductive tract and imposes criminal penalties for violations.

28 Oct 2026

Macromolecular crowding helps control synthetic DNA droplet formation

Macromolecular crowding can serve as a design tool for controlling the formation and organization of synthetic DNA droplets, a study from Science Tokyo reveals.

28 Oct 2026

Engineered albumin could lead to needle-free, long-lasting protein medicines

Protein-based medicines have transformed the treatment of many diseases, but they often come with a limitation: they must be injected, sometimes repeatedly, because they are rapidly cleared from the bloodstream.

28 Oct 2026

Adalvo expands biosimilars portfolio through acquisition of romiplostim biosimilar program from Enzene

Adalvo today announced the acquisition of a romiplostim biosimilar program referencing Nplate® from Enzene, strengthening its biosimilars portfolio and accelerating the company’s expansion into complex biological medicines.

From Adalvo 28 Oct 2026

Prolific announces major new investments and partnerships with NantWorks and Zylidac Bio CDMO

On the heels of our exciting major investment and Nantworks partnership announcement last week, Prolific Machines is pleased to announce a great new partnership with Zylidac Bio, a fully integrated biologics CDMO located next door to us in San Francisco Bay Area, to scale up the production of Prolific's Optogentics-enabled cell lines for clinical and GMP manufacturing!

From Prolific Machines, Inc. 28 Oct 2026

Atelerix and Frontier Space partner to enable biological sample preservation for space missions

Atelerix, a biotech company revolutionizing cell preservation and biological transport with its pioneering hydrogel encapsulation technology, today announced a partnership with Frontier Space, a UK based space biotechnology company building platform technology for in-orbit R&D and biomanufacturing.

From Atelerix Ltd 28 Oct 2026

Lab-on-a-chip technology helps predict childhood leukemia treatment responses

More than 120,000 people in the U.S. are living with acute lymphoblastic leukemia (ALL), and 6,000 new cases are diagnosed each year. Of those, more than 3,500 will be in children.

27 Oct 2026